In the latest 2017 revisions of the McDonald criteria also [19], the International Panel on the Diagnosis of MS has recommended that testing for anti-AQP4 and anti-MOG antibodies should be performed, when available, in patients with features of NMOSD. This evidence concerns the gene AQP4 and myeloid sarcoma.